Alan Nelson

Alan Nelson, currently serving as the Chairman and CEO of NeoPath, has significantly contributed to the field of biomedical technology by leading the development of the world’s first fully-automated AI-driven platform designed to detect cervical cancer. Prior to his tenure at NeoPath, Nelson was the Executive Director of the Biodesign Institute at Arizona State University. His academic career is distinguished, having held professorships at prestigious institutions including ASU, the University of Washington, MIT, and Harvard. Nelson’s extensive research in biomedical imaging is well-documented, with more than 100 peer-reviewed publications to his name. He also holds over 100 U.S. patents, underscoring his prolific contributions to medical technology and innovation. Nelson received his Ph.D. in Physics from the University of California, Berkeley, further solidifying his expertise in the scientific community.